HDAC9 and synovial sarcoma: HDAC inhibitors have been shown to disrupt the SS18-SSX/TLE1/ATF2 protein complex [9, 11], providing an explanation for the sensitivity of synovial sarcoma cells to HDAC inhibition [15].